Cornerstone Investment Partners LLC Takes $240,000 Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Cornerstone Investment Partners LLC bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 9,908 shares of the company’s stock, valued at approximately $240,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health during the 4th quarter valued at approximately $28,000. Raleigh Capital Management Inc. raised its position in shares of Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares in the last quarter. US Bancorp DE raised its position in shares of Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company’s stock valued at $47,000 after acquiring an additional 1,508 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at approximately $48,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 17,303 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $48.14, for a total transaction of $832,966.42. Following the completion of the sale, the insider now directly owns 193,601 shares in the company, valued at approximately $9,319,952.14. This trade represents a 8.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Soleil Boughton sold 268,932 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the sale, the insider now owns 169,803 shares of the company’s stock, valued at $4,712,033.25. The trade was a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,062,011 shares of company stock worth $36,892,724 in the last quarter. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Stock Down 9.8 %

Shares of HIMS stock opened at $40.65 on Tuesday. The stock has a 50-day simple moving average of $36.83 and a 200 day simple moving average of $26.99. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98. The stock has a market capitalization of $9.03 billion, a P/E ratio of 92.39 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on HIMS. Bank of America upped their price target on Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a research report on Thursday, February 20th. Citigroup upped their price target on Hims & Hers Health from $25.00 to $27.00 and gave the company a “sell” rating in a research report on Tuesday, February 25th. Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Leerink Partners increased their target price on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 25th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus target price of $37.23.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.